. 2022 May 25;13:883655. doi: 10.3389/fphar.2022.883655

TABLE 2.

List of the studies involving OS in this meta-analysis.

First author	Year	NCT	Trial name	Total number	Phase	Canner type	Treatment 1	Patient number	Treatment 2	Patient number	Follow-up time	OS HR	OS CI lower limit	OS CI upper limit
Fehrenbacher L et al. (Fehrenbacher et al., 2016)	2016	NCT01903993	POPLAR	287	2	Non small cell lung cancer	Atezolizumab	144	Docetaxel	143	13	0.73	0.53	0.99
Fehrenbacher L et al. (Fehrenbacher et al., 2018)	2018	NCT02008227	OAK	1225	3	Non small cell lung cancer	Atezolizumab	613	Docetaxel	612	26	0.80	0.70	0.92
Powles T et al. (Powles et al., 2018)	2017	NCT02302807	IMvigor211	234	3	Urothelial carcinoma	Atezolizumab	116	Chemotherapy	118	17.3	0.87	0.63	1.21
Eng C et al. (Eng et al., 2019)	2019	NCT02788279	IMblaze370	180	3	Colorectal cancer	Atezolizumab	90	Regorafenib	90	7.3	1.19	0.83	1.71
Pujol JL et al. (Pujol et al., 2019)	2018	NCT03059667	IFCT-1603	73	2	Small cell lung cancer	Atezolizumab	49	Chemotherapy	24	13.7	0.84	0.45	1.58
Herbst RS et al. (Herbst et al., 2020)	2020	NCT02409342	IMpower110	554	3	Non small cell lung cancer	Atezolizumab	277	Chemotherapy	277	13.4	0.83	0.65	1.07
Bang YJ er al (Bang et al., 2018)	2018	NCT02625623	JAVELIN Gastric 300	371	3	Gastric/gastrooesophageal junction cancer	Avelumab	185	Chemotherapy	186	10.6	1.1	0.9	1.4
Park K et al. (Park et al., 2021)	2021	NCT02395172	JAVELIN Lung 200	529	3	Non small cell lung cancer	Avelumab	264	Docetaxel	265	24	0.87	0.71	1.05
Pujade-Lauraine E et al. (Pujade-Lauraine et al., 2021)	2021	NCT02580058	JAVELIN Ovarian 200	378	3	Ovarian cancer	Avelumab	188	Pegylated liposomal doxorubicin	190	T1:18.2	1.14	0.95	1.58
											T2:17.4
Huang J et al. (Huang et al., 2020)	2020	NCT03099382	ESCORT	448	3	Squamous cell carcinoma	Camrelizumab	228	Chemotherapy	220	8.3	0.71	0.57	0.87
Sezer A et al. (Sezer et al., 2021)	2021	NCT03088540	EMPOWER-Lung 1	563	3	Non small cell lung cancer	Cemiplimab	283	Chemotherapy	280	T1:10.8	0.57	0.42	0.77
											T2:10.9
Siu LL et al. (Siu et al., 2019)	2019	NCT02319044	CONDOR	267	2	Squamous cell carcinoma	Durvalumab+	133	Durvalumab	67	T1:6.5	0.99	0.69	1.43
	2019	NCT02319044	CONDOR	267	2	Squamous cell carcinoma	Tremelimumab	133	Durvalumab	67	T2:6.0	0.99	0.69	1.43
					2	Squamous cell carcinoma	Durvalumab+	133	Tremelimumab	67	T1:6.5	0.72	0.51	1.03
					2	Squamous cell carcinoma	Tremelimumab	133	Tremelimumab	67	T2:5.2	0.72	0.51	1.03
Ferris RL et al. (Ferris et al., 2020)	2020	NCT02369874	EAGLE	736	3	Squamous cell carcinoma	Durvalumab	240	Standard of care	249	T1:7.6 T2:7.8	0.88	0.72	1.08
					3	Squamous cell carcinoma	Durvalumab+	247	Standard of care	249	T1:6.3	1.04	0.85	1.26
							Tremelimumab				T2:7.8
Planchard D et al. (Planchard et al., 2020)	2020	NCT02352948	ARCTIC	595	3	Non small cell lung cancer	Durvalumab	62	Standard of care	64	9.1	0.63	0.42	0.93
					3	Non small cell lung cancer	Durvalumab+ Tremelimumab	174	Standard of care	118	9.1	0.80	0.61	1.05
					3	Non small cell lung cancer	Durvalumab	117	Standard of care	118	9.1	0.80	0.59	1.08
					3	Non small cell lung cancer	Tremelimumab	60	Standard of care	118	9.1	1.02	0.71	1.46
Powles T et al. (Powles et al., 2020)	2020	NCT02516241	DANUBE	1032	3	Urothelial carcinoma	Durvalumab	346	Chemotherapy	344	41.2	0.99	0.83	1.17
					3	Urothelial carcinoma	Durvalumab+	342	Chemotherapy	344	41.2	0.85	0.72	1.02
							Tremelimumab
Rizvi NA et al. (Rizvi et al., 2020)	2020	NCT02453282	MYSTIC	488	3	Non small cell lung cancer	Durvalumab	163	Chemotherapy	162	30.2	0.76	0.56	1.02
					3	Non small cell lung cancer	Durvalumab+	163	Chemotherapy	162	30.2	0.85	0.61	1.17
							Tremelimumab
Bachelot T et al. (Bachelot et al., 2021)	2021	NCT02299999	SAFIR02-BREAST IMMUNO	199	2	Breast cancer	Durvalumab	68	Chemotherapy	131	19.7	0.84	0.54	1.29
Hodi FS et al. (Hodi et al., 2010)	2010	NCT00094653	MDX010-20	273	3	Melanoma	Ipilimumab	137	Gp100	136	T1:27.8 T2:17.2	0.66	0.51	0.87
Tarhini AA et al. (Tarhini et al., 2020)	2020	NA	E1609	1159	3	Melanoma	Ipilimumab	523	Interferon Alfa-2b	636	57.4	0.78	0.61	0.99
Borghaei H et al. (Borghaei et al., 2015)	2015	NCT01673867	CheckMate 057	582	3	Non small cell lung cancer	Nivolumab	292	Docetaxel	290	13.2	0.73	0.59	0.89
Brahmer J et al. (Brahmer et al., 2015)	2015	NCT01642004	CheckMate 017	272	3	Non small cell lung cancer	Nivolumab	135	Docetaxel	137	11	0.59	0.44	0.79
Motzer RJ et al. (Motzer et al., 2015)	2015	NCT01668784	CheckMate 025	821	3	Renal cell carcinoma	Nivolumab	410	Everolimus	411	14	0.73	0.57	0.93
Ferris RL et al. (Ferris et al., 2016)	2016	NCT02105636	CheckMate 141	361	3	Squamous cell carcinoma	Nivolumab	240	Standard therapy	121	5.1	0.70	0.51	0.96
Hodi FS et al. (Hodi et al., 2016)	2016	NCT01927419	CheckMate 069	142	2	Melanoma	Nivolumab+	95	Ipilimumab	47	24.5	0.74	0.43	1.26
							Ipilimumab
Carbone DP et al. (Carbone et al., 2017)	2017	NCT02041533	CheckMate 026	541	3	Non small cell lung cancer	Nivolumab	271	Chemotherapy	270	13.5	1.08	0.87	1.34
Hodi FS et al. (Hodi et al., 2018)	2018	NCT01844505	CheckMate 067	945	3	Melanoma	Nivolumab+ Ipilimumab	314	Ipilimumab	315	T1:46.9 T2:18.6	0.54	0.44	0.67
					3	Melanoma	Nivolumab	316	Ipilimumab	315	T1: 36 T2:18.6	0.65	0.53	0.79
Larkin J et al. (Larkin et al., 2018)	2018	NCT01721746	CheckMate 037	405	3	Melanoma	Nivolumab	272	Chemotherapy	133	24	0.95	0.73	1.24
Hellmann MD et al. (Hellmann et al., 2019)	2019	NCT02477826	CheckMate 227	1166	3	Non small cell lung cancer	Nivolumab+ Ipilimumab	583	Chemotherapy	583	29.3	0.73	0.64	0.84
Kato K et al. (Kato et al., 2019)	2019	NCT02569242	ATTRACTION-3	419	3	Squamous cell carcinoma	Nivolumab	210	Chemotherapy	209	17.6	0.77	0.62	0.96
Wu YL et al. (Wu et al., 2019)	2019	NCT02613507	CheckMate 078	504	3	Non small cell lung cancer	Nivolumab	338	Docetaxel	166	8.8	0.68	0.52	0.90
Motzer RJ et al. (Motzer et al., 2020)	2020	NCT02231749	CheckMate 214	1096	3	Renal cell carcinoma	Nivolumab+	550	Sunitinib	546	42	0.72	0.61	0.86
							Ipilimumab
Reardon DA et al. (Reardon et al., 2020)	2020	NCT02017717	CheckMate 143	369	3	Glioblastoma	Nivolumab	184	Bevacizumab	185	9.5	1.04	0.83	1.3
Robert C et al. (Robert et al., 2020)	2020	NCT01721772	CheckMate 066	418	3	Melanoma	Nivolumab	210	Dacarbazine	208	60	0.50	0.40	0.63
Zamarin D et al. (Zamarin et al., 2020)	2020	NCT02498600	NRG GY003	100	2	Ovarian cancer	Nivolumab+	51	Nivolumab	49	NA	0.79	0.44	1.42
							Ipilimumab
Baas P et al. (Baas et al., 2021)	2021	NCT02899299	CheckMate 743	605	3	Malignant pleural mesothelioma	Nivolumab+	303	Chemotherapy	302	29.7	0.74	0.60	0.91
							Ipilimumab
Spigel DR et al. (Spigel et al., 2021)	2021	NCT02481830	CheckMate 331	569	3	Small cell lung cancer	Nivolumab	284	Chemotherapy	285	15.8	0.86	0.72	1.04
Tannir NM et al. (Tannir et al., 2021)	2021	NA	CheckMate 214	139	3	Renal cell carcinoma	Nivolumab+	74	Sunitinib	65	42	0.45	0.30	0.70
							Ipilimumab
Ribas A et al. (Ribas et al., 2013)	2013	NCT00257205	NA	655	3	Melanoma	Tremelimumab	328	Chemotherapy	327	NA	0.88	NA	NA
Herbst RS et al. (Herbst et al., 2016)	2016	NCT01905657	KEYNOTE-010	687	2/3	Non small cell lung cancer	Pembrolizumab	344	Docetaxel	343	13.1	0.71	0.58	0.88
Hamid O et al. (Hamid et al., 2017)	2017	NCT01704287	KEYNOTE-002	359	2	Melanoma	Pembrolizumab	180	Chemotherapy	179	28	0.86	0.67	1.10
Shitara K et al. (Shitara et al., 2018)	2018	NCT02370498	KEYNOTE-061	395	3	Gastric/gastrooesophageal junction cancer	Pembrolizumab	196	Paclitaxel	199	8.5	0.82	0.66	1.03
Cohen EEW et al. (Cohen et al., 2019)	2019	NCT02252042	KEYNOTE-040	495	3	Squamous cell carcinoma	Pembrolizumab	247	Standard of care	248	7.5	0.80	0.65	0.98
Fradet Y et al. (Fradet et al., 2019)	2019	NCT02256436	KEYNOTE-045	542	3	Urothelial cancer	Pembrolizumab	270	Chemotherapy	272	27.7	0.70	0.57	0.85
Mok TSK et al. (Mok et al., 2019)	2019	NCT02220894	KEYNOTE-042	1274	3	Non small cell lung cancer	Pembrolizumab	637	Chemotherapy	637	12.8	0.81	0.71	0.93
Reck M et al. (Reck et al., 2019)	2019	NCT02142738	KEYNOTE-024	305	3	Non small cell lung cancer	Pembrolizumab	154	Chemotherapy	151	25.2	0.63	0.47	0.86
Robert C et al. (Robert et al., 2019)	2019	NCT01866319	KEYNOTE-006	834	3	Melanoma	Pembrolizumab	556	Ipilimumab	278	57.7	0.73	0.61	0.88
Kojima T et al. (Kojima et al., 2020)	2020	NCT02564263	KEYNOTE-181	628	3	Esophageal cancer	Pembrolizumab	314	Chemotherapy	314	7.1	0.89	0.75	1.05
Popat S et al. (Popat et al., 2020)	2020	NCT02991482	ETOP 9-15	144	3	Malignant pleural mesothelioma	Pembrolizumab	73	Chemotherapy	71	17.5	1.04	0.66	1.67
Shitara K et al. (Shitara et al., 2020)	2020	NCT02494583	KEYNOTE-062	506	3	Gastric/gastrooesophageal junction cancer	Pembrolizumab	256	Chemotherapy	250	29.4	0.91	0.69	1.18
Powles T et al. (Powles et al., 2021)	2021	NCT02853305	KEYNOTE-361	659	3	Urothelial carcinoma	Pembrolizumab	307	Chemotherapy	352	31.7	0.92	0.77	1.11
Winer EP et al. (Winer et al., 2021)	2021	NCT02555657	KEYNOTE-119	622	3	Breast cancer	Pembrolizumab	312	Chemotherapy	310	31.4	0.97	0.82	1.15

OS = Overall survival. HR = Hazard ratio. CI = Confidence interval.